Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

類似資料

• A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors
  著者:: Zhang, Yong, 等
  出版事項: (2018)
• Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases
  著者:: Walid Shalata, 等
  出版事項: (2025-09-01)
• Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
  著者:: Kim, Hye Sook, 等
  出版事項: (2013)
• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
  著者:: Offin, Michael, 等
  出版事項: (2018)
• Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer: To Test or Not to Test?
  著者:: Gazdar, Adi F.
  出版事項: (2011)